Echo Therapeutics, Inc.
10 Forge Parkway
Franklin,
MA 02038
United States - Map
Phone: 508-553-8850
Fax: 508-553-8720
Web Site: http://www.echotx.com
| Echo Therapeutics, Inc., a medical device and specialty pharmaceutical company, is developing a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system for people with diabetes and for use in hospital critical care units, and for people with diabetes and a wide range of transdermal reformulations of specialty pharmaceutical products previously approved by the United States Food and Drug Administration. It offers Symphonytm tCGM System, a next-generation, non-invasive (needle-free), wireless tCGM system designed to provide on-demand blood glucose data. The company is developing Preludetm SkinPrep System as transdermal skin permeation device for its Symphony tCGM System to enhance the flow of interstitial fluids and molecules across the protective membrane of the stratum corneum, the outmost protective layer of the skin; and SonoPrep System, a skin permeation system that incorporates its patented skin permeation control technology and utilizes ultrasound as a skin permeation medium to enhance the flow of interstitial fluids and molecules across the protective membrane of the stratum corneum. The company was founded in 1989 and is based in Franklin, Massachusetts. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Patrick T. Mooney M.D., 41
Chairman, Chief Exec. Officer and Pres |
$
300.00K | N/A | Dr. Robert S. Langer Ph.D., 61
Co-Founder, Chairman of the Scientific Advisory Board |
$
42.00K | N/A | Mr. Harry G. Mitchell CPA, 58
Chief Operating Officer, Chief Financial Officer, Principal Accounting Officer, Sec. and Treasurer |
$
250.00K | N/A | Dr. Joseph Kost D.Sc., 62
Co-Founder and Chief Scientific Officer |
N/A
| N/A | Mr. Barry D. Marston ,
VP of Sales & Marketing |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.22% Nasdaq 
Profile
